Jeffrey Sherman

“Fourth quarter total revenue increased by 11% over prior year to $190 million. Total clinical revenue continued with strong double-digit growth and increased 16% from prior years.”

“Third quarter total revenue grew sequentially by 4% from Q2 and increased by 12% over prior year to $188 million. Total clinical revenue continued with strong double-digit growth and increased by 18% from prior year.”

“We saw continued earnings momentum in Q1 with another quarter of positive adjusted EBITDA growing 102% over the prior year to positive $7 million. The combination of clinical test volume growth and improvements in revenue per test due to test mix and RCM initiatives continue to drive revenue growth.”

“We are excited about what you and your team are working on and you're already having an impact on our R&D efforts. We are executing our margin expansion initiatives to deliver sustainable growth.”

“I'll begin with a little more detail on our operating results for the quarter. As Chris said, we started the year with revenue experiencing double-digit growth over the prior year.”